Skip to main content

Table 2 Duration of disease by source at registration with DILT1D study team

From: Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D)

T1D duration Clinics Internet Register
Less than 100 days a 24 (9%) 33 (12%) 1 (0.4%)
Between 100 days and two years b 56 (21%) 85 (31%) 47 (17%)
Two years or more 1 (0.4%) 24 (9%) 1 (0.4%)
  1. aNewly diagnosed T1D.
  2. bRecently diagnosed T1D.
  3. Numbers given are of individuals in each group category where data was available (N = 272).